1. Khoury, D.S., et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27, 1205-1211 (2021).
2. Earle, K.A., et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423-4428 (2021).
3. Plotkin, S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 17, 1055-1065 (2010).
4. Chen, R.T., et al. Measles antibody: reevaluation of protective titers. J Infect Dis 162, 1036-1042 (1990).
5. Woudenberg, T., et al. Additional Evidence on Serological Correlates of Protection against Measles: An Observational Cohort Study among Once Vaccinated Children Exposed to Measles. Vaccines (Basel) 7(2019).
6. Goldschneider, I., Gotschlich, E.C. & Artenstein, M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129, 1307-1326 (1969).
7. Feng, S., et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. medRxiv, 2021.2006.2021.21258528 (2021).
8. Gilbert, P.B., et al. Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv, 2021.2008.2009.21261290 (2021).
9. Siber, G.R. Methods for estimating serological correlates of protection. Dev Biol Stand 89, 283-296 (1997).
10. Andrews, N., Borrow, R. & Miller, E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin.Diagn.Lab Immunol. 10, 780-786 (2003).
11. Siber, G.R., et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 25, 3816-3826 (2007).
12. Gundlapalli, A.V., et al. SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response. Open Forum Infect Dis 8, ofaa555 (2021).
13. Kristiansen, P.A., et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet 397, 1347-1348 (2021).
14. Case, J.B., et al. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host Microbe 28, 475-485 e475 (2020).
15. Tan, C.W., et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol 38, 1073-1078 (2020).
16. Jurgens, G. Low Dose Regimens of BNT162b2 mRNA Vaccine Exceed SARS-Cov-2 Correlate of Protection Estimates for Symptomatic Infection, in those 19-55 Years of Age. medRxiv, 2021.2003.2006.21253058 (2021).
17. Jodar, L., et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21, 3265-3272 (2003).
18. Brewer, R.C., Ramadoss, N.S., Lahey, L.J., Robinson, W.H. & Lanz, T.V. BNT162b2 Vaccine Induces Divergent B cell responses to SARS-CoV-2 S1 and S2. medRxiv, 2021.2007.2020.21260822 (2021).
19. Li, B., et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. medRxiv, 2021.2007.2007.21260122 (2021).
20. Bergwerk, M., et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med (2021).
21. Carreño, J.M., et al. Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37. medRxiv, 2021.2007.2021.21260961 (2021).
22. Goldblatt, D., et al. Cross-sectional prevalence of SARS-CoV-2 antibodies in healthcare workers in paediatric facilities in eight countries. J Hosp Infect 110, 60-66 (2021).
23. Johnson, M., et al. Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2. J Clin Virol 130, 104572 (2020).
24. Krammer, F., et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med 384, 1372-1374 (2021).
25. Shen, X., et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 29, 529-539 e523 (2021).
26. Hutson, A.D. Calculating nonparametric confidence intervals for quantiles using fractional order statistics. Journal of Applied Statistics 26, 343-353 (1999).
27. Pilishvili, T., et al. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021. MMWR Morb Mortal Wkly Rep 70, 753-758 (2021).